First in vivo MRI study on theranostic dendrimersomes

JOURNAL OF CONTROLLED RELEASE

卷:248

Article

Filippi, Miriam¹  Catanzaro, Valeria¹  Patrucco, Deyssy¹  Botta, Mauro²  Tei, Lorenzo²  Terreno, Enzo¹ 

[1] Univ Torino, Centro Imaging Molecolare Preclinico, Dipartimento Biotecnol Molecolari Scienze Salute, Via Nizza 52, I-10126 Turin, Italy

[2] Univ Piemonte Orientale Amedeo Avogadro, Dipartimento Scienze Innovazione Tecnolog, Viale T Michel 11, Alessandria 15121, Italy

关键词: Dendrimersomes;    Prednisolone Phosphate;    Melanoma;    Theranostic;    Magnetic Resonance Imaging;   

DOI  :  10.1016/j.jconrel.2017.01.010

来源: Elsevier

【 摘 要 】

Amphiphilic Janus-dendrimers are able to self-assemble into nanosized vesicles named dendrimersomes. We recently synthesized the 3,5-C-12-EG-(OH)(4) dendrimer that generates dendrimersomes with very promising safety and stability profiles, that can be loaded with different contrast agents for in vivo imaging. In this contribution, nanovesicles were loaded with both the Magnetic Resonance Imaging (MRI) reporter GdDOTAGA(C-18)(2) and the glucocorticoid drug Prednisolone Phosphate (PLP), in order to test their effective potential as theranostic nanocarriers on murine melanoma tumour models. The incorporation of GdDOTAGA(C-18)(2) into the membrane resulted in dendrimersomes with a high longitudinal relaxivity (r(1) = 39.1 mM(-1) s(-1), at 310 K and 40 MHz) so that, after intravenous administration, T-1-weighted MRI showed a consistent contrast enhancement in the tumour area. Furthermore, the nanovesicles encapsulated PLP with good efficiency and displayed anti-tumour activity both in vitro and in vivo, thus enabling their practical use for biomedical theranostic applications. (C) 2016 Published by Elsevier B.V.

【 授权许可】

Free